# A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors

> **NCT01469130** · PHASE1 · COMPLETED · sponsor: **Array Biopharma, now a wholly owned subsidiary of Pfizer** · enrollment: 21 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** MEK162

## Key facts

- **NCT ID:** NCT01469130
- **Lead sponsor:** Array Biopharma, now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2014-04
- **Final completion:** 2018-02-01
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2020-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01469130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01469130, "A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01469130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*